← Back to Search

FLT-PET for Neuroblastoma

N/A
Waitlist Available
Led By Anthony F. Shields, M.D., Ph.D.
Research Sponsored by Barbara Ann Karmanos Cancer Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

The purpose of this study is to gain knowledge about how to best diagnose and treat tumors, how tumors affect normal tissue and how treatment of tumors with radiation therapy and chemotherapy affect tumors.

Eligible Conditions
  • Neuroblastoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: FLT-PETExperimental Treatment1 Intervention
Patients will be managed per COG protocol ANBL00B1 (low risk, LR), ANBL0521 (intermediate risk, IR), ANBL0531 (high risk, HR) or other future neuroblastoma studies according to their risk group (risk assignment, treatment schema and protocols are available in COG website). The following is a brief description of the treatment. 1. Low risk patients: observation only. 2. Intermediate risk patients: chemotherapy stratified according to risk sub-groups followed by surgical resection. 3. High risk patients: 6 courses of induction chemotherapy, surgical resection and high dose chemotherapy with autologous stem cell transplant (SCT), involved field radiation and 6 months of Isotrenitoin. PET scan will be conducted at diagnosis, at the end of the first cycle of treatment and prior to the surgical procedure (resection).
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
FLT-PET
2015
Completed Phase 1
~130

Find a Location

Who is running the clinical trial?

Barbara Ann Karmanos Cancer InstituteLead Sponsor
164 Previous Clinical Trials
9,198 Total Patients Enrolled
2 Trials studying Neuroblastoma
63 Patients Enrolled for Neuroblastoma
Children's Hospital of MichiganOTHER
25 Previous Clinical Trials
4,136 Total Patients Enrolled
1 Trials studying Neuroblastoma
23 Patients Enrolled for Neuroblastoma
Anthony F. Shields, M.D., Ph.D.Principal InvestigatorBarbara Ann Karmanos Cancer Institute
~3 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top